These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245 [TBL] [Abstract][Full Text] [Related]
7. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer. Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A Cells; 2020 Jun; 9(6):. PubMed ID: 32498368 [TBL] [Abstract][Full Text] [Related]
8. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Genßler S; Burger MC; Zhang C; Oelsner S; Mildenberger I; Wagner M; Steinbach JP; Wels WS Oncoimmunology; 2016 Apr; 5(4):e1119354. PubMed ID: 27141401 [TBL] [Abstract][Full Text] [Related]
9. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942 [TBL] [Abstract][Full Text] [Related]
10. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Rezvani K; Rouce RH Front Immunol; 2015; 6():578. PubMed ID: 26635792 [TBL] [Abstract][Full Text] [Related]
11. The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy. Fabian KP; Hodge JW Mol Ther Oncolytics; 2021 Dec; 23():266-276. PubMed ID: 34761106 [TBL] [Abstract][Full Text] [Related]
12. Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment. Oberschmidt O; Kloess S; Koehl U Front Immunol; 2017; 8():654. PubMed ID: 28649246 [TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells. Hojjatipour T; Sharifzadeh Z; Maali A; Azad M Hum Cell; 2023 Nov; 36(6):1843-1864. PubMed ID: 37477869 [TBL] [Abstract][Full Text] [Related]
14. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells. Klaihmon P; Luanpitpong S; Kang X; Issaragrisil S Cancer Cell Int; 2023 Nov; 23(1):297. PubMed ID: 38012684 [TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Hu Y; Tian ZG; Zhang C Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014 [TBL] [Abstract][Full Text] [Related]
16. NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells. Zhuang X; Long EO Front Immunol; 2022; 13():840844. PubMed ID: 35585985 [TBL] [Abstract][Full Text] [Related]
17. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy. Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS Front Immunol; 2019; 10():2683. PubMed ID: 31798595 [TBL] [Abstract][Full Text] [Related]
18. Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells. Klaihmon P; Kang X; Issaragrisil S; Luanpitpong S Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445684 [TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects. Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037 [TBL] [Abstract][Full Text] [Related]
20. NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy. Suck G; Odendahl M; Nowakowska P; Seidl C; Wels WS; Klingemann HG; Tonn T Cancer Immunol Immunother; 2016 Apr; 65(4):485-92. PubMed ID: 26559813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]